The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters



    PHILADELPHIA and LONDON, Sept. 4 /CNW/ - Thomson Reuters, the world's
leading source of intelligent information for businesses and professionals,
announced today that the National Cancer Institute (NCI) has joined the
community of scientists worldwide using BIOMARKERcenter, the first
comprehensive resource for biomarker intelligence to provide pharmaceutical,
biotechnology, diagnostic, and research organizations with a framework for
assessing and tracking a potential biomarker for use at any stage of research
or development.
    Specifically, the National Cancer Institute's Developmental Therapeutics
program and the associated Biomarker Program will integrate BIOMARKERcenter
into its continuing efforts to investigate novel chemical and biological
agents for their potential to improve cancer therapeutics.
    "The NCI's Developmental Therapeutics Program (DTP) and its clinical
counterpart, the Cancer Treatment Evaluation Program (CTEP) have been using
Integrity(R) and it's predecessor, Ensemble(R), for many years as sources of
current and earlier information on agents at all phases of discovery and
clinical trials related to cancer," said Dave Newman, Chief, Natural Products
Branch DCTD/DTP, NCI. "The availability of BIOMARKERcenter and its integration
with Integrity will now permit easier integration of animal and human
biomarker information at all stages of the NCI's drug discovery and
development programs within the Division of Cancer Treatment and Diagnosis,
the parent organization of DTP and CTEP."
    Using a unique lifecycle approach to indicate the stage of a given
biomarker, BIOMARKERcenter covers individual biomarker usage as identified in
literature, patents, conferences, clinical trial information, and other
sources for all major therapeutic areas. For each therapy area, it includes
not only biomarkers with established clinical usage, but also emerging uses
for the biomarker.  Each record is manually curated and expertly indexed to
allow searching by fields such as name, type, biological process, indication,
population, role, measurement technique, substrate, lifecycle stage, and
development status of diagnostic kits.   Each record is further enriched with
links to all supporting source documents, throughout the history of the
biomarker.
    "The Scientific business of Thomson Reuters was the first to deliver a
truly structured approach to a previously fragmented field," said Dr Josep
Prous, Vice President and Chief Scientific Officer, Pharmaceutical and
Chemical Markets, Thomson Reuters. "We feel very proud to work with the
National Cancer Institute, a true leader in the field of cancer research."
    The National Cancer Institute was founded in 1937 with a mandate to
conduct and foster cancer research; review and approve grant-in-aid
applications to support promising research projects on the causes, prevention,
diagnosis, and treatment of cancer; and provide training and instruction in
the diagnosis and treatment of cancer. Since its creation, the National Cancer
Institute has evolved into one of the world's pre-eminent cancer research
organizations.
    For more information about BIOMARKERcenter, please go to:
http://scientific.thomsonreuters.com/products/biomarkercenter/

    
    About National Cancer Institute
    
    The National Cancer Institute (NCI) is a component of the National
Institutes of Health (NIH), one of eight agencies that compose the Public
Health Service (PHS) in the Department of Health and Human Services (DHHS).
The NCI, established under the National Cancer Institute Act of 1937, is the
U.S. Federal Government's principal agency for cancer research and training.
The National Cancer Act of 1971 broadened the scope and responsibilities of
the NCI and created the National Cancer Program. Over the years, legislative
amendments have maintained the NCI authorities and responsibilities and added
new information dissemination mandates as well as a requirement to assess the
incorporation of state-of-the-art cancer treatments into clinical practice.

    
    About Thomson Reuters
    
    Thomson Reuters is the world's leading source of intelligent information
for businesses and professionals.  We combine industry expertise with
innovative technology to deliver critical information to leading decision
makers in the financial, legal, tax and accounting, scientific, healthcare and
media markets, powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs more than 50,000 people in 93 countries. For more
information, go to www.thomsonreuters.com.





For further information:

For further information: Eoin Bedford, Scientific, +44-(0)-2074334691,
eoin.bedford@thomsonreuters.com, Web Site: http://www.thomsonreuters.com,
http://www.scientific.thomson.com


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890